Bangladesh vs Cape Verde: Average cost of multi drug-resistant tuberculosis treatment
Bangladesh
466 constant 2022 US$
in 2024
Cape Verde
500 constant 2022 US$
in 2024
Bangladesh rank
81st
Cape Verde rank
78th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bangladesh
- Cape Verde
How they compare
Cape Verde currently reports 500 constant 2022 US$ against 466 constant 2022 US$ in Bangladesh, a difference of 34 constant 2022 US$.
That makes Cape Verde's figure about 1.1 times Bangladesh's.
The two have swapped places 4 times across 8 shared years of data; in 2017 it was Cape Verde ahead.
Bangladesh ranks 81st and Cape Verde ranks 78th of 92 countries.
Cape Verde has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bangladesh | Cape Verde | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,374 constant 2022 US$ | 1,500 constant 2022 US$ | 126 constant 2022 US$ | Cape Verde |
| 2020s | 769 constant 2022 US$ | 1,100 constant 2022 US$ | 331 constant 2022 US$ | Cape Verde |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bangladesh or Cape Verde?
- Cape Verde, at 500 constant 2022 US$ against 466 constant 2022 US$ in Bangladesh as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bangladesh and Cape Verde?
- 34 constant 2022 US$, with Cape Verde ahead.
- How many years of comparable data are there for Bangladesh and Cape Verde?
- 8 years are reported by both, from 2017 to 2024.
- How do Bangladesh and Cape Verde rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bangladesh ranks 81st and Cape Verde ranks 78th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.